sorafenib has been researched along with birb 796 in 18 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 137 | 5 | 80 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 12 (66.67) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
Knight, ZA; Shokat, KM | 1 |
Gray, NS; Liu, Y | 1 |
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Getlik, M; Grütter, C; Klüter, S; Naqvi, T; Pawar, V; Rabiller, M; Rauh, D; Simard, JR | 1 |
Dietrich, J; Hulme, C; Hurley, LH | 1 |
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
Russu, WA; Shallal, HM | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Engel, J; Grütter, C; Nguyen, HD; Phan, T; Rauh, D; Richters, A; Simard, JR | 1 |
Ding, K; Li, Y; Lu, X; Ren, X | 1 |
Alder, J; Benitez, R; Davidson, C; Davies, MP; Hayes, JM; Jakupovic, S; Martinez, A; Perez, C; Rzepecka, K; Welsby, P | 1 |
Bukhtiyarova, M; Karpusas, M; Lee, Y; Namboodiri, HV; Ramcharan, J; Springman, EB | 1 |
Liu, H; Shen, Y; Yang, Y; Yao, X | 1 |
Eriksson, LA; Gao, C; Grøtli, M | 1 |
2 review(s) available for sorafenib and birb 796
Article | Year |
---|---|
Features of selective kinase inhibitors.
Topics: Animals; Drug Evaluation, Preclinical; Humans; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Substrate Specificity | 2005 |
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
16 other study(ies) available for sorafenib and birb 796
Article | Year |
---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Rational design of inhibitors that bind to inactive kinase conformations.
Topics: Binding Sites; Drug Design; Humans; Models, Molecular; Phosphotransferases; Protein Kinase Inhibitors; Protein Structure, Tertiary | 2006 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Displacement assay for the detection of stabilizers of inactive kinase conformations.
Topics: Crystallography, X-Ray; Drug Design; Mitogen-Activated Protein Kinase 9; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Urea | 2010 |
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib | 2010 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification of type II and III DDR2 inhibitors.
Topics: Discoidin Domain Receptors; Drug Design; Fluorescence; High-Throughput Screening Assays; Ligands; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structure-Activity Relationship | 2014 |
Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β.
Topics: Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Glycogen Synthase Kinase 3 beta; Humans; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuroprotective Agents; Phosphorylation; Structure-Activity Relationship; Substrate Specificity; tau Proteins | 2021 |
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Topics: Benzamides; Benzenesulfonates; Crystallography, X-Ray; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Topics: Allosteric Regulation; Benzamides; Benzenesulfonates; Catalytic Domain; Humans; Imatinib Mesylate; Indenes; Mitogen-Activated Protein Kinase 14; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Thermodynamics | 2011 |
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2 | 2015 |